6 clinical trials found.
-
A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine if talquetamab is safe and useful for treating patients with multiple myeloma and to assess how the ... -
A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
The purpose of the study is to evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care in Mayo ... -
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma Grade IIIb Follicular Lymphoma transformed lymphoma and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
The purpose of the study is to evaluate the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for patients ... -
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
The purpose of the study is to evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M +Len) compared with rituximab in combination ... -
A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
This is a study to see if a new medicine called epcoritamab (works by binding to CD3 and CD20 on cells, which brings T cells ...
-
A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 AN ANTI-CD22 X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY IN COMBINATION WITH ODRONEXTAMAB AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY IN PATIENTS WITH AGGRESSIVE
The goal of this study is to investigate how safe and effective the combining of two different antibodies, REGN5837 and odronextamab (REGN1979), is in patients ...
![](/static/img/icon_loading.gif)